1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Fuji Pharma Co., Ltd.

Fuji Pharma Co., Ltd.

9.85
EUR
-0.15
(-1.50%)
339.56MMarket Cap
Nov 10Next Earn
Fuji Pharma Co., Ltd.
DUS:FUP
(Dusseldorf Stock Exchange)

Recent

price

9.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
765.42
822.02
762.12
891.43
987.47
1,041.38
1,144.18
1,182.44
1,266.64
1,188.36
1,084.59
1,265.14
1,458.27
1,682.58
1,897.84
2,117.72
- -
Revenue per Share
75.53
83.82
48.55
73.23
70.24
68.77
70.8
110.3
112.67
97.02
66.92
90.52
110.98
141.35
252.81
122.94
- -
Basic EPS, GAAP
17.31
-28.6
-17.04
10.76
24.88
-31.36
62.01
56.67
71.6
122.87
101.26
78.05
-538.46
-81.48
-9.09
79.79
- -
Free Cash Flow per Basic Share
12.99
16.61
18.98
18.48
20.04
22.19
22.53
23.52
26.53
27.48
29.01
30.04
30.01
36.99
39.98
42.46
- -
Dividend per Share
692.83
753
782.52
852.16
913.24
956.09
976.8
1,089.14
1,181.3
1,263.51
1,282.41
1,345.55
1,473.62
1,694.13
1,873.87
1,917.87
1,966.17
Book Value per Share
689.2
748.98
779.44
706.8
765.19
826.48
874.52
998.63
1,107.1
1,157.58
1,189.37
1,246.85
1,045.38
1,262.36
1,362.03
1,347.81
1,440.6
Tangible Book Value per Share
26
26
28
28
30
30
30
30
30
31
31
27
24
24
24
24
25
Basic Weighted Avg Shares
19,702
21,624
21,522
25,174
29,215
31,680
34,229
35,387
37,909
36,279
33,793
33,990
35,426
40,889
46,138
51,677
- -
Sales/Revenue/Turnover
19.98
19.89
16.24
12.97
10.87
10.27
10.44
12.2
11.59
11.52
9.3
9.85
10.67
9.45
8.42
9.66
- -
Operating Margin (%)
1,027
1,021
1,211
1,413
1,653
2,079
1,921
2,023
2,251
2,129
2,057
2,106
2,745
3,023
3,680
3,965
- -
Depreciation Expense
1,944
2,205
1,371
2,068
2,078
2,092
2,118
3,301
3,372
2,962
2,085
2,432
2,696
3,435
6,146
3,000
- -
Net Income, GAAP
38.41
36.95
41.06
37.94
35.67
32.59
32.69
27.11
24.58
25.2
28.51
27.83
27.56
21.89
25.71
25
- -
Effective Tax Rate (%)
9.87
10.2
6.37
8.21
7.11
6.6
6.19
9.33
8.89
8.16
6.17
7.16
7.61
8.4
13.32
5.81
- -
Profit Margin (%)
10,531
12,949
14,794
14,855
20,450
19,725
19,570
21,695
23,381
21,907
23,971
14,642
10,752
9,343
6,671
16,925
22,021
Working Capital
- -
- -
- -
4,417
5,890
4,627
4,596
3,780
4,534
7,544
9,034
9,141
13,452
11,924
6,285
13,074
11,827
LT Debt
17,833
21,265
22,098
24,065
28,543
28,592
29,225
32,599
35,348
39,363
39,960
32,680
35,803
41,174
45,561
46,905
51,360
Total Equity
10.56
10.29
5.73
7.21
5.93
6.04
6.69
8.36
8.35
6.82
4.34
4.61
4.84
4.59
3.92
4.82
- -
Return on Invested Capital (%)
11.07
10.65
5.86
7.76
6.28
5.93
6.07
9.04
8.73
6.6
4.12
4.77
4.93
5.39
8.68
4.25
- -
Return on Capital (%)
11.42
11.28
6.32
8.96
7.9
7.32
7.33
10.68
9.93
7.93
5.26
6.7
7.87
8.93
14.17
6.49
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Mar'24
Dec'26
Mar'26
ST Debt
20,912
- -
17,789
LT Borrowings
2,083
- -
8,003
LT Finance Leases
4,311
- -
3,824
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
26
Market Capitalization
- -
45,413
62,284

Working Capital

JPY

•

in mil. unless spec.
Mar'24
Dec'26
Mar'26
Total Current Assets
39,793
- -
54,315
Cash, Cash Equivalents & STI
1,375
- -
10,887
Accounts Receivable, Net
16,357
- -
17,301
Inventories
20,850
- -
24,501
Total Current Liabilities
32,133
- -
32,294
Payables & Accruals
- -
- -
- -
ST Debt
20,912
- -
17,789
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.5%
3.99%
2.95%
Free Cash Flow
-212.95%
-382.41%
-981%
Net Income, GAAP
10.01%
16.53%
-51.19%
Sales/Revenue/Turnover
5.25%
9.01%
12.01%
Total Cash Common Dividend
4.81%
3.52%
6.58%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,746
10,642
- -
- -
46,138
2025
- -
- -
- -
- -
51,677
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
112.69
62.44
- -
- -
252.81
2025
- -
- -
- -
- -
122.94
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
39.98
2025
- -
- -
- -
- -
42.46
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Fuji Pharma Co., Ltd. engages in the research, development, manufacture, and marketing of pharmaceutical products primarily in Japan with international operations. The company's core product offerings include injection agents, internal drugs, drugs for external use, and diagnostic products. Fuji Pharma specializes notably in hormone medicines for obstetrics and gynecology, injectable drugs for radiological use such as radiopaque dyes for urinary tracts and blood vessels, and generic drugs in the women's healthcare area. It also produces pharmaceutical excipients including unique formulations like Fujicalin, F-Melt, and FujiSil. Founded in 1965, the company is headquartered in Chiyoda-ku, Tokyo, Japan. In recent developments, Fuji Pharma has been advancing its mid-term business plan focusing on three growth strategies: Women’s Healthcare, Biosimilars, and Global Contract Manufacturing Organization (CMO) services. The company has expanded strategic partnerships, including a notable collaboration with Alvotech to co-develop and commercialize biosimilar products, now covering six biosimilar candidates. Fuji Pharma also continues to enhance production capabilities with new manufacturing lines for high-potency injectable syringes and has aligned its sustainability initiatives with the Science Based Targets initiative (SBTi) to reduce greenhouse gas emissions. These efforts reflect a significant strategic shift aiming at expanding global biosimilars and contract manufacturing business segments while reinforcing its foothold in women’s health pharmaceuticals. Fuji Pharma operates within the pharmaceutical industry focusing on healthcare, biosimilars, and medical product manufacturing segments. The company serves healthcare providers, hospitals, and pharmaceutical distributors both domestically and internationally. Fuji Pharma leverages its extensive product portfolio and technological innovation to address demands in obstetrics, gynecology, radiology, and general medicine sectors. It maintains a parent-company relationship with Fuji Pharmaceutical Holdings. The combination of legacy pharmaceutical products and cutting-edge biosimilars underpins Fuji Pharma’s comprehensive market approach for growth and sustained competitiveness.